Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15

Clozapine As Transformative Treatment In Bipolar Patients

Authors Wilkowska A, Cubała WJ

Received 15 August 2019

Accepted for publication 19 September 2019

Published 9 October 2019 Volume 2019:15 Pages 2901—2905

DOI https://doi.org/10.2147/NDT.S227196

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Roger Pinder


Alina Wilkowska, Wiesław J Cubała

Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland

Correspondence: Alina Wilkowska
Department of Psychiatry, Medical University of Gdańsk, Dębinki 7, Gdańsk 80-211, Poland
Tel +48 58 349 2650
Fax +48 349 2748
Email ali.wilkowska@gmail.com

Abstract: Clozapine is an atypical antipsychotic used in treatment-resistant bipolar disorder. There is evidence for its anti-suicidal, anti-aggressive properties and efficacy in substance use comorbidities. Despite guidelines, the drug is used in 1.5% of bipolar patients only. Considering its effectiveness in treatment-resistant cases as well as its epigenetic effects it may become transformative treatment in bipolar disorder impacting the clinical course and psychosocial burden of the disease.

Keywords: clozapine, transformative treatment, bipolar disorder, treatment resistance


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]